Do self-perpetuating B lymphocytes drive human autoimmune disease?

Immunology

Volumn 97, Issue 2, 1999, Pages 188-196

  Edwards, J C W ^a   Cambridge, G ^a   Abrahams, V M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD20 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RHEUMATOID FACTOR;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOPATHOGENESIS; INFLAMMATION; MEMORY CELL; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; RHEUMATOID FACTOR;

EID: 0033033201     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00772.x     Document Type: Review

References (43)

1. LINDHOUT E., KOOPMAN G., PALS S.T. & DE GROOT C. (1997) Triple check for antigen specificity of B cells during germinal centre reactions. Immunol Today 18, 573.
2. FEARON D.T. & CARTER R.H. (1995) The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 13, 127.
3. ROITT I.M. (1991) Principles of autoimmunity. In: Clinical Immunology, (eds. J. Brostoff, G. K. Scadding, M. Male & I. M. ROITT) CHAPTER 4, 41 10. GOWER MEDICAL PUBLISHING, LONDON.
4. GLYNN L.E. (1975) Rheumatic Fever. In: Clinical Aspects of Immunology, (eds G.H. Gell, R. R. A. Coombs & P. J. LACHMANN) Chapter 38, p. 1079. Blackwell Scientific Publications, Oxford.
5. CHIOCCHIA G., BOISSIER M.C., MANOURY B. & FOURNIER C. (1993) T cell regulation of collagen-induced arthritis in mice. Immunomodulation of arthritis by cytotoxic T cell hybridomas specific for type II collagen. Eur J Immunol 23, 327.
6. MATTESON E.L., COHEN M.D. & CONN D.L. (1998) Rheumatoid arthritis; clinical features and systemic involvement. In: Rheumatology; (ed. J.H. KLIPPEL & P.A. DIEPPE), pp. 5.4.1.4.8. Mosby, London.
7. TOIVANEN A. (1998) Reactive arthritis and Reiter's syndrome; history and clinical features. In: Rheumatology; (Eds J.H. KLIPPEL & P.A. DIEPPE), pp. 6.11.1.11.8. Mosby, London.
8. PULENDRAN B., VAN DRIEL R. & NOSSAL G.J. (1997) Immunological tolerance in germinal centres. Immunol Today 18, 27.
9. CARSON D.A. (1993) Rheumatoid factor In: Textbook of Rheumatology, (eds. W. N. Kelley, E. D. Harris, S. Ruddy & C. B. SLEDGE), pp. 155 W. B. SAUNDERS, PHILADELPHIA.
10. DAVIES K.A. (1996) Complement, immune complexes and systemic lupus erythematosus. Br J Rheumatol 35, 5.
11. GULDNER H.H., SZOSTECKI C., VOSBERG H.P., LAKOMEK H.J., PENNER E., & BAUTZ F.A. (1986) Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosome 94, 132.
12. MURRAY K.J., SZER W., GROM A.A. et al. (1997) Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoids arthritis and iridocyclitis: selective association with MHC gene. J Rheumatol 24, 560.
13. EDWARDS J.C.W. (1999) Is rheumatoid factor relevant. In: Rheumatoid Arthritis; Questions and Uncertainties (eds. H. Bird & M. L. SNAITH) Chapter I. Blackwell Scientific, Oxford.
14. WELCH M.J., FONG S., VAUGHAN J. & CARSON D. (1983) Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol 51, 299.
15. THOMPSON K.M., RANDEN I., BRREIZEN M., FORRE O. & NATVIG J.B. (1994) Variable region gene useage of human monoclonal rheumatoid factors derived from healthy donors following immunization. Eur J Immunol 24, 165.
16. BORRETZEN M., RANDEN I., ZDARSKY E., FORRE O., NATVIG J.B. & THOMPSON K.M. (1994) Control of autoantibody affinity by selection against amino acid replacements in the complementarity-determining regions. Proc Natl Acad Sci USA 91, 129171.
17. KARRAS J.G., WANG Z., HUO L., HOWARD R.G., FRANK D.A. & ROTHSTEIN T.L. (1997) Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med 185, 1035.
18. CAPRA J.D., WINCHESTER R.J. & KUNKEL H.G. (1971) Hypergamma-globulinemic purpura. Studies on the unusual anti-γ-globulins characteristic of the sera of these patients. Medicine 50, 125.
19. MANNIK M. & NARDELLA F.A. (1985) IgG rheumatoid factors and self association of these antibodies. Clin Rheumatic Dis 11, 551.
20. VERSENDAAL H., JONKER M., BRESNIHAN B. et al. (1999) Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum in press.
21. BHATIA A., BLADES S., CAMBRIDGE G. & EDWARDS J.C.W. (1998) Differential distribution of FcγRIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenviroments. Immunology 94, 65.
22. KLASSEN R.J.L., GOLDSCHEMEDING R., TETTEROO P.A.T. & VON DEM BORNE A.E.G.K. (1988) The Fc Valency of an immune complex is the decisive factor for binding to low-affinity Fcγ receptors. Eur J Immunol 18, 1373.
23. van DE WINKEL J.G.J. & CAPEL P.J.A. (1993) Human IgG Fc receptor heterogenity: molecular aspects and clinical implications. Immunol Today 14, 215.
24. ABRAHAMS V.M., CAMBRIDGE G. & EDWARDS J.C.W. (1998) FcγRIIIa mediates TNFα secretion by human monocytes/macrophages. Br J Rheumatol 37 (Abstracts Suppl) 1, 90.
25. DEBETS J.M.H., VAN DE WINKEL J.G.J., CEUPPENS J.L., DIETEREN I.E.M. & BURMAN W.A. (1990) Cross-linking of both FcγRI and FcγII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc FcγR interactions. J Immunol 144, 1304.
26. VOICE J. & LACHMANN P.J. (1997) Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur J Immunol 27, 2514.
27. MORGAN A., JONES N.D., NESBITT A.M., CHAPLIN L., BODMER M.W. & EMTAGE J.S. (1995) The N terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcgR1 and FcgRIII binding. Immunology 86, 319.
28. EDWARDS J.C.W. & SUTTON B.J. (1998) What does IgG look like? Br J Rheumatol 37 (Abstracts Suppl) 1, 7.
29. SERINO G., PITINGOLO F., GRANATIERI C. et al. (1983) Hypergammaglobulinemic purpura of Waldenström: characterisation of circulating immune complexes. Acta Haemat 69, 152.
30. EDWARDS J.C.W., LEIGH R.D. & CAMBRIDGE G. (1997) Expression of molecules involved in B lymphocyte survival and differentiation by synovial fibroblasts. Clin Exp Immunol 108, 407.
31. ROOSNEK E. & LANZAVECCHIA A. (1991) Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 173, 487.
32. SARMAY G., KONEZ G., PECINI I. & GERGERLY J. (1997) Fc gamma receptor type IIb induced recruitment of inositol and protein phosphatases to the signal transductory complex of human B cells, Immunol Lett 57, 159.
33. JEFFERIS R. (1995) Rheumatoid factors, B cells and immunoglobulin genes. Br Med Bull 51, 312.
34. KIRCHNER T., HOPPE F., SCHALKE B. & MULLER-HERMELINK H.K. (1988) Microenvironment of thymic myoid cells in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 54, 295.
35. TOURTELLOTTE W.W., WALSH M.J., BAUMHEFNER R.W., STAUGAITIS S.M. & SHAPSHAK P. (1984) The current status of multiple sclerosis intra-blood brain-barrier IgG synthesis. Ann N Y Acad Sci 436, 52.
36. GAY F.W., DRYE T.J., DICK G.W. & ESIRI M.M. (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 120, 1461.
37. ALARCON-SEGOVIA D., RUIZ-ARGUELLES A. & LLORENTE L. (1996) Broken dogma: penetration of autoantibodies into living cells. Immunol Today 17, 163.
38. VAISHNAW A.K., MCNALLY J.D. & ELKON K.B. (1997) Apoptosis in the rheumatic diseases. Arthritis Rheum 40, 1917.
39. CRAFT J. & HARDIN J.A. (1993) Antinuclear antibodies. In: Textbook of Rheumatology (eds. W. N. Kelley, E. D. Harris, S. Ruddy & C. B. SLEDGE), pp. 164. W. B. SAUNDERS, PHILADELPHIA.
40. PILATTE Y., TISSERAND E.M., GREFFARD A., BIGNON J. & LAMBRE C.R. (1990) Anticarbohydrate autoantibodies to sialidase-treated erythrocytes and thymocytes in serum from patients with pulmonary sarcoidosis. Am J Med 88, 486.
41. MALONEY D.G., GRILLO-LOPEZ A.J., BODKIN D.J. et al. (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15, 3266.
42. ISAACS J.D., WATTS R.A., HAZLEMAN B.L. et al. (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340, 748.
43. MCLAUGHLIN P., GRILLO-LOPEZ A.J., LINK B.K. et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16, 2825. Additional data on file, Roche Products, Welwyn, UK.